THE NEXT BIG DRUG BREAKTHROUGH!
“Regulatory approval processes for IMYN have been initiated in several countries. Additionally, in both the US and Europe preparations for clinical trials are underway. Research indicates that it has the potential to affect neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), autoimmune disorders such as Multiple Sclerosis (MS), and a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU).”
“We have a drug that is fully developed, which our Scientific Advisory Board believes has demonstrated safety and efficacy for indications for which we hope the treatment will be approved. We are in the marketplace raising awareness and are cognizant of the need to set up a viable distribution system. We are at the cutting-edge of where drug development and therapies are today. The two Orphan Diseases for which Argyll Biotechnologies plans to seek FDA approval in the US are Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy (RSD or RSDS). However, the overall target market is potentially broader. It could include indications such as Multiple Sclerosis (MS), from which an estimated 2.5 million people suffer worldwide. There is also the potential to be used in treating complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU). Worldwide, approximately 246 million people have Diabetes Mellitus, of those, 1 in 6 will develop a foot ulcers and an estimated 50% have a Diabetic Neuropathy (DN). Therefore, there is certainly a large potential market. From a business standpoint as well as a humanitarian standpoint, we feel there is great potential.”
- Stephen D. Ferrone, CEO
